Skip to main content

Table 5 Serum tumor marker levels of patients with different subtypes of lung cancer in the test group (\( \overline{\mathrm{X}} \) ±s)

From: Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer

Project SCLC NSCLC P Value LADC LSCC P Value
Before treatment
CEA (ng/ml) 96.73 ± 9.11 96.01 ± 9.31 0.65 95.54 ± 9.78 95.82 ± 9.12 0.86
NSE (ng/ml) 88.71 ± 7.43 88.61 ± 7.51 0.94 88.63 ± 7.49 88.59 ± 7.49 0.97
CYFRA21-1 (ng/ml) 37.87 ± 5.87 37.84 ± 5.90 0.98 37.82 ± 5.88 37.85 ± 5.89 0.96
CA199 U/ml 51.78 ± 7.48 51.84 ± 7.52 0.96 51.82 ± 7.52 51.85 ± 7.51 0.98
After treatment
 CEA (ng/ml) 24.66 ± 1.55 20.25 ± 1.1 <  0.0001 20.27 ± 1.08 20.24 ± 1.09 0.87
 NSE (ng/ml) 28.15 ± 1.97 22.81 ± 1.75 <  0.0001 22.83 ± 1.73 22.79 ± 1.73 0.89
 CYFRA21-1 (ng/ml) 10.13 ± 0.13 9.55 ± 0.22 <  0.0001 9.54 ± 0.21 9.57 ± 0.2 0.38
 CA199 U/ml 29.22 ± 2.62 24.16 ± 1.7 <  0.0001 24.14 ± 1.72 24.17 ± 1.71 0.92
\